RecruitingPHASE1, PHASE2NCT05668741
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Intervention
- VX-522 mRNA therapy(drug)
- Enrollment
- 39 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2023 – 2027
Study locations (30)
- University of Alabama at Birmingham - Child Health Research Unit, Birmingham, Alabama, United States
- Memorial Health Services on behalf of Long Beach Memorial Medical Center d/b/a Miller Children's Hospital Long Beach, Long Beach, California, United States
- Stanford University - Palo Alto - Pulmonology, Palo Alto, California, United States
- National Jewish Health, Denver, Colorado, United States
- Shands Hospital - Pulmonology, Gainesville, Florida, United States
- Northwestern Memorial Hospital - Feinberg Pavilion, Chicago, Illinois, United States
- Clinical & Translational Science Unit (CTSU) - Pulmonology, Kansas City, Kansas, United States
- PAREXEL International - Baltimore, Baltimore, Maryland, United States
- The Johns Hopkins University - Johns Hopkins Hospital - Pulmonology, Baltimore, Maryland, United States
- MGH - MGfC Pediatric Cystic Fibrosis Center, Boston, Massachusetts, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- University of Minnesota -Pulmonology, Minneapolis, Minnesota, United States
- St. Louis Children's Hospital - Pulmonology, St Louis, Missouri, United States
- Medicine at East 85th Street, New York, New York, United States
- Presbyterian Hospital - Pulmonology, New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Moderna, Inc
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05668741 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.
- RECRUITINGPHASE1NCT07283770Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNCT07363304Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.Meyer Children's Hospital IRCCS